HC Wainwright Cuts Valneva (NASDAQ:VALN) Price Target to $18.00

Valneva (NASDAQ:VALN) had its price objective cut by HC Wainwright from $19.00 to $18.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Valneva’s Q1 2025 earnings at ($0.38) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.31) EPS.

Valneva Trading Up 3.4 %

VALN opened at $4.90 on Thursday. The firm has a market cap of $398.17 million, a price-to-earnings ratio of -37.69 and a beta of 1.93. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50. The business’s 50 day moving average is $4.29 and its two-hundred day moving average is $5.77. The company has a quick ratio of 2.25, a current ratio of 2.78 and a debt-to-equity ratio of 0.70.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC boosted its stake in Valneva SE (NASDAQ:VALN) by 33.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 118,000 shares of the company’s stock after acquiring an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 as of its most recent SEC filing. 11.39% of the stock is currently owned by institutional investors and hedge funds.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.